b3 bio signed an agreement with Roche to source and develop innovative early-stage technologies that could result in potential therapeutic benefits. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as provide development funds.
b3 bio and Roche started their partnership in July, 2008. The initial arrangement focused on the development of delivery systems for a range of drug candidates and diagnostic cargos.
